Under the terms of the deal, Lifecore investors are slated to receive $6.28 in cash per share. The package also includes one non-transferable contingent value right per share, which offers potential future payments tied to specific revenue and EBITDA performance milestones through 2030. Juan Monteverde, lead attorney at the firm, is now reviewing the transaction to determine if the valuation reflects the company's true market potential.
Investors concerned about the fairness of the arrangement can contact the firm for a review of their legal options. Monteverde & Associates, which operates out of the Empire State Building, emphasizes its track record in securities litigation as it evaluates the impact of the acquisition on minority shareholders.
Comments (0)
No comments yet. Be the first!